Blog - Biotech Consulting & Biologics Development

Innovation

How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 1

What if the secret to healthier, longer lives is quietly discarded in hospital operating rooms every day?

Innovation

How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 1

What if the secret to healthier, longer lives is quietly discarded in hospital operating rooms every day?

Innovation

How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 1

What if the secret to healthier, longer lives is quietly discarded in hospital operating rooms every day?

CMC and Bioprocess Blog

Execution-focused articles on CMC strategy, bioprocess scale-up, tech transfer, CDMO selection, and GMP readiness for process development scientists and manufacturing leaders scaling biologics into regulatory-ready therapies.

Innovation

How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 1

What if the secret to healthier, longer lives is quietly discarded in hospital operating rooms every day?

Bioprocessing

How to Use Media Supplements to Tailor Biosimilar Glycan Quality to Your Reference Product in Two Rounds

Today we’re talking about one of the most frustrating bottlenecks in biosimilar development: how to screen efficiently a long list of quality-modulating compounds when your standard tools

Bioprocessing

Why a Single Large DoE Fails Biosimilar Glycan Optimization — And the Parallel Screening Method That Actually Works

Today we’re talking about one of the most frustrating bottlenecks in biosimilar development: how to screen efficiently a long list of quality-modulating compounds when your standard tool

Innovation

How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) – Part 2

T cell therapies promise life-changing outcomes for cancer patients, but their personalized, patient-specific nature throws a wrench into the classic centralized manufacturing playbook.

Innovation

How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) – Part 1

Cell and gene therapies represent a revolutionary advance in personalized medicine, offering hope where traditional biologics and small molecules have struggled.

Innovation

Nitrosamine Risk Assessment and CRO Selection: The $6 Million Mistake CMC Teams Must Avoid – Part 2

Getting an NDA signed shouldn’t feel like waiting for FDA approval. If your CRO needs weeks just to kickstart paperwork…

Bioprocessing

How to Use Media Supplements to Tailor Biosimilar Glycan Quality to Your Reference Product in Two Rounds

Today we’re talking about one of the most frustrating bottlenecks in biosimilar development: how to screen efficiently a long list of quality-modulating compounds when your standard tools

Bioprocessing

Why a Single Large DoE Fails Biosimilar Glycan Optimization — And the Parallel Screening Method That Actually Works

Today we’re talking about one of the most frustrating bottlenecks in biosimilar development: how to screen efficiently a long list of quality-modulating compounds when your standard tool

Innovation

How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 1

What if the secret to healthier, longer lives is quietly discarded in hospital operating rooms every day?

Innovation

How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) – Part 2

T cell therapies promise life-changing outcomes for cancer patients, but their personalized, patient-specific nature throws a wrench into the classic centralized manufacturing playbook.

Innovation

How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) – Part 1

Cell and gene therapies represent a revolutionary advance in personalized medicine, offering hope where traditional biologics and small molecules have struggled.

Innovation

Nitrosamine Risk Assessment and CRO Selection: The $6 Million Mistake CMC Teams Must Avoid – Part 2

Getting an NDA signed shouldn’t feel like waiting for FDA approval. If your CRO needs weeks just to kickstart paperwork…

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.

No spam. Unsubscribe anytime.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.

No spam. Unsubscribe anytime.

Innovation

How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 1

Dr. David Brühlmann

Innovation

How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 1

Dr. David Brühlmann

Innovation

How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 1

Dr. David Brühlmann

CMC and Bioprocess Blog

Innovation

How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 1

Bioprocessing

How to Use Media Supplements to Tailor Biosimilar Glycan Quality to Your Reference Product in Two Rounds

Bioprocessing

Why a Single Large DoE Fails Biosimilar Glycan Optimization — And the Parallel Screening Method That Actually Works

Innovation

How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) – Part 2

Innovation

How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) – Part 1

Innovation

Nitrosamine Risk Assessment and CRO Selection: The $6 Million Mistake CMC Teams Must Avoid – Part 2

Bioprocessing

How to Use Media Supplements to Tailor Biosimilar Glycan Quality to Your Reference Product in Two Rounds

Bioprocessing

Why a Single Large DoE Fails Biosimilar Glycan Optimization — And the Parallel Screening Method That Actually Works

Innovation

How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 1

Innovation

How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) – Part 2

Innovation

How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) – Part 1

Innovation

Nitrosamine Risk Assessment and CRO Selection: The $6 Million Mistake CMC Teams Must Avoid – Part 2

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.